Communiqués Black Diamond Therapeutics, Inc.

Actions

BDTX

US09203E1055

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX Autres places de cotation 20:37:51 02/07/2026			Varia. 5j.	Varia. 1 janv.
1,985 ^USD	+7,88%		+15,00%	-19,55%

21/05	Black Diamond Therapeutics annonce des résultats de Phase 2 positifs pour le silevertinib dans le traitement de première ligne du CPNPC présentant des mutations non classiques de l'EGFR	CI
07/05	Black Diamond Therapeutics, Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI

Communiqués

22/05	Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference	GL
21/05	Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations	GL
19/05	Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC	GL
19/05	Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC	AQ
07/05	Black Diamond: Q1 Earnings Snapshot	AQ
07/05	Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update	GL
21/04	Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting	GL
16/03	Black Diamond: Q4 Earnings Snapshot	AQ
16/03	Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update	GL
02/03	Black Diamond Therapeutics to Participate in Upcoming Investor Conferences	GL
03/12	Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM	GL
02/12	Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update	GL
06/11	Black Diamond Therapeutics to Participate in Upcoming Investor Conferences	GL
06/11	Black Diamond: Q3 Earnings Snapshot	AQ
06/11	Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update	GL
07/08/25	Black Diamond: Q2 Earnings Snapshot	AQ
07/08/25	Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update	GL
29/05/25	Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference	GL
29/05/25	Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference	AQ
12/05/25	Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update	GL
31/03/25	Black Diamond Therapeutics to Participate in Upcoming Investor Conferences	GL
19/03/25	Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy	AQ
19/03/25	Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy	GL
06/03/25	Black Diamond: Q4 Earnings Snapshot	AQ
06/03/25	Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update	GL